Shop TB-500
TB-500 at the cellular workshop
A rat wound experiment with full thymosin beta-4 opened this subject up for me. Skin coverage, collagen and small vessels changed together, with each repair job measured separately.
A rat skin-wound experiment
In the 1999 wound study by Malinda and colleagues, rats received full-length thymosin beta-4. New skin coverage increased by 42% at 4 days and up to 61% at 7 days compared with saline. The wounds also contracted more and accumulated more collagen and small blood vessels. Several kinds of repair were happening in the same experiment.
That is a much richer result than the phrase “faster healing” suggests. I like the separable jobs here: a surface being covered, supporting material being laid down, a blood supply developing underneath. The paper gives each of those jobs some substance. It also gives this TB-500 story its first complication: the experiment used the larger thymosin beta-4 protein.
TB-500 peptide and thymosin beta-4
The TB-500 peptide is a synthetic chain of seven amino acids, Ac-LKKTETQ, corresponding to positions 17–23 of thymosin beta-4. The parent protein contains 43 amino acids. Analytical work on TB-500 identifies the short fragment; the broader thymosin beta-4 review describes the protein used in most repair experiments.
The distinction matters to the workshop analogy. A small component can be interesting without doing every job of the larger assembly. Full thymosin beta-4 can also yield Ac-SDKP, a separate fragment with anti-fibrotic and angiogenic activity that TB-500 cannot produce. I distrust a claim that quietly assigns the whole assembly’s work to its short fragment.
Skin cells, collagen and a blood supply
Re-epithelialization is the resurfacing of a wound. In the same wound paper, skin cells also travelled farther in a laboratory migration assay. Collagen deposition and new-vessel growth were additional findings in the rats. Those are connected observations, with different things being measured.
The thymosin beta-4 literature on cell movement and tissue remodeling helps explain why the protein turns up in so many repair discussions. The biology is what excites me: cells moving into a gap, a scaffold of tissue changing around them, vessels taking shape. A useful human treatment would need to bring those processes together safely. The published TB-500 fragment record has no completed controlled human trial establishing that result.
After the wound closes
A wound experiment is a good beginning for this subject, though it leaves plenty of work on the table. The muscle study in dystrophin-deficient mice counted more regenerating fibers while finding no significant improvement in strength, heart function or fibrosis. Elsewhere, a pig heart experiment found no reduction in ischemia-reperfusion injury, the damage associated with stopping and restoring blood flow.
Those results complicate my use of “repair” as a single score. Skin coverage, muscle force and heart performance deserve their own examinations. The research tour moves between those jobs; new blood vessels deserve a room of their own because the same processes raise tumor concerns.
Before a human claim
The early intravenous safety study involved full-length thymosin beta-4 in healthy adults. The short fragment still lacks a validated human benefit or safety profile. The 2026 sports-medicine review describes encouraging animal work alongside scarce human safety data and potential for serious harm.
TB-500 has no FDA approval for human use. On FDA’s page current as of April 22, 2026, its nomination is withdrawn and it is no longer listed in Category 2; that status supplies neither approval nor a clear compounding permission. The legal-status page sets out the dated record.